Literature DB >> 8634524

Tumor necrosis factor alpha immunoreactivity of rat peritoneal mast cell granules decreases during early secretion induced by compound 48/80: an ultrastructural immunogold morphometric analysis.

W J Beil1, G R Login, M Aoki, L O Lunardi, E S Morgan, S J Galli, A M Dvorak.   

Abstract

We used fast (seconds) and ultrafast (milliseconds) microwave energy-assisted chemical fixation protocols, postembedding immunogold staining, and a morphometric analysis to investigate the early morphological changes and the TNF-alpha immunoreactivity in the cytoplasmic granules of rat peritoneal mast cells that had been stimulated to secrete by exposure to compound 48/80. Exposure to compound 48/80 induced the development of increased numbers of cytoplasmic granules that exhibited decreased electron density; these granules often also appeared swollen. These granule alterations were accompanied by a significantly decreased proportion of granules that were positive for TNF-alpha immunoreactivity. We also calculated the density of TNF-alpha labeling/mu 2 in both dense (unaltered) and altered granules in specimens. TNF-alpha immunoreactivity was present in dense granules (regardless of whether or not the specimens had been stimulated with compound 48/80) and in cells that were fixed with either fast or ultrafast microwave energy. However, altered granules exhibited a decreased density of TNF-alpha label. These findings show that changes in the immunolocalization and/or density of TNF-alpha immunoreactivity occur very rapidly upon stimulation of rat peritoneal mast cells with compound 48/80.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8634524     DOI: 10.1159/000237267

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  7 in total

Review 1.  Control of death receptor ligand activity by posttranslational modifications.

Authors:  R Weinlich; T Brunner; G P Amarante-Mendes
Journal:  Cell Mol Life Sci       Date:  2010-03-20       Impact factor: 9.261

2.  Munc13 proteins control regulated exocytosis in mast cells.

Authors:  Elsa M Rodarte; Marco A Ramos; Alfredo J Davalos; Daniel C Moreira; David S Moreno; Eduardo I Cardenas; Alejandro I Rodarte; Youlia Petrova; Sofia Molina; Luis E Rendon; Elizabeth Sanchez; Keegan Breaux; Alejandro Tortoriello; John Manllo; Erika A Gonzalez; Michael J Tuvim; Burton F Dickey; Alan R Burns; Ruth Heidelberger; Roberto Adachi
Journal:  J Biol Chem       Date:  2017-11-15       Impact factor: 5.157

3.  Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility.

Authors:  Abigail E Russi; Mark E Ebel; Yuchen Yang; Melissa A Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-29       Impact factor: 11.205

4.  Mast cell inhibition attenuates myocardial damage, adverse remodeling, and dysfunction during fulminant myocarditis in the rat.

Authors:  Yair Mina; Shunit Rinkevich-Shop; Eli Konen; Orly Goitein; Tammar Kushnir; Frederick H Epstein; Micha S Feinberg; Jonathan Leor; Natalie Landa-Rouben
Journal:  J Cardiovasc Pharmacol Ther       Date:  2012-11-19       Impact factor: 2.457

5.  The tetraspanin CD63 is required for efficient IgE-mediated mast cell degranulation and anaphylaxis.

Authors:  Stefan Kraft; Marie-Hélène Jouvin; Nitin Kulkarni; Sandra Kissing; Ellen S Morgan; Ann M Dvorak; Bernd Schröder; Paul Saftig; Jean-Pierre Kinet
Journal:  J Immunol       Date:  2013-08-14       Impact factor: 5.422

Review 6.  Mast Cells and Innate Lymphoid Cells: Underappreciated Players in CNS Autoimmune Demyelinating Disease.

Authors:  Melissa A Brown; Rebecca B Weinberg
Journal:  Front Immunol       Date:  2018-03-21       Impact factor: 7.561

7.  Mast cell hyperactivity underpins the development of oxygen-induced retinopathy.

Authors:  Kenshiro Matsuda; Noriko Okamoto; Masatoshi Kondo; Peter D Arkwright; Kaoru Karasawa; Saori Ishizaka; Shinichi Yokota; Akira Matsuda; Kyungsook Jung; Kumiko Oida; Yosuke Amagai; Hyosun Jang; Eiichiro Noda; Ryota Kakinuma; Koujirou Yasui; Uiko Kaku; Yasuo Mori; Nobuyuki Onai; Toshiaki Ohteki; Akane Tanaka; Hiroshi Matsuda
Journal:  J Clin Invest       Date:  2017-10-09       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.